Articles tagged with Parkinsons Disease
A new study by Rush University Medical Center researchers found that a sudden decrease in testosterone levels may cause Parkinson's-like symptoms in male mice. Testosterone supplementation reversed the pathology in the mice. The study suggests that preserving testosterone levels may be important to prevent Parkinson's disease.
Research in Taiwan found a link between stopping cholesterol medication and an increased risk of developing Parkinson's disease. Fat-soluble statins were associated with a reduced risk, while hydrophilic statins showed no such correlation.
Researchers at Scripps Research Institute discover that parkin enzyme loss leads to reduced levels of protective protein Fbw7β, causing neuronal stress and death. Targeting Fbw7β may offer a new neuroprotective strategy for Parkinson's disease and other neurodegenerative disorders.
Researchers at Banner Sun Health Research Institute and Mayo Clinic are working together on a diagnostic test to identify early Parkinson's disease in patients. They believe that transcutaneous submandibular gland biopsy may provide the needed accuracy, as they look for a protein in the cells from patients with early Parkinson's disease.
This study examines how Parkinson's disease affects the health-related quality of life in northeastern Sicily, Italy. The researchers applied the ecological model to investigate the individual and social environmental factors impacting patient outcomes, including depression, cognitive impairment, coping strategies, and family size.
A recent Penn study found a significant association between cerebrovascular disease and dementia, particularly in younger patients with Alzheimer's disease. The researchers suggest that early management of vascular risk factors and healthy lifestyles may delay or prevent the onset of dementia due to Alzheimer's and Parkinson's disease.
Researchers found two distinct strains of alpha-synuclein that promote different patterns of misfolding, leading to unique sets of symptoms in neurodegenerative disorders. The study suggests that different structural shapes of the protein may contribute to co-occurrence of synuclein and tau accumulations in certain brain diseases.
Researchers have discovered that a single protein, alpha-synuclein, can exist in two different structural shapes, or 'strains', which promote misfolding of other disease proteins commonly found in Alzheimer's and Parkinson's. This finding has significant implications for the development of therapies for neurodegenerative diseases.
Researchers propose a new motion test that examines various walking features in healthy and clinical populations, identifying critical changes in mobility. The study uses advanced mathematical computations to extract data from accelerometer signals, showing significant differences between healthy and clinical groups.
Lauren Sciences LLC has received a second grant from the Michael J. Fox Foundation to further develop its V-Smart therapeutic platform for treating Parkinson's disease. The grant will investigate the efficacy of V-Smart vesicles in delivering GDNF to brain regions affected by PD.
Researchers at Scripps Research Institute design a dual inhibitor attacking leucine-rich repeat kinase 2 (LRRK2) and c-jun-N-terminal kinase (JNK) enzymes, two proteins closely linked to Parkinson's disease development. The compound may offer a more effective treatment by eliminating complications of individual inhibitors.
Researchers have found that diapocynin, a synthetic antioxidant molecule, protects neurobehavioral function in mice with Parkinson's Disease symptoms. The treatment prevented expected deficits in motor coordination, suggesting potential therapeutic benefits.
Researchers at Tel Aviv University found that mannitol prevents clumps of α-synuclein protein from forming in the brain, a process characteristic of Parkinson's disease. Mannitol has been shown to reduce aggregates of α-synuclein in genetically-altered flies and mice.
A new University of Florida study suggests a brain-imaging technique can help diagnose movement disorders. The diffusion tensor imaging technique was used on 72 patients with movement disorder diagnoses, with high accuracy achieved in separating the patients into disorder groups.
Scientists at the Vienna University of Technology have observed and explained the dance of atoms on iron-oxide surfaces. They found that carbon monoxide is the partner responsible for rapid motion, which leads to clustering and reduces the effectiveness of catalysts. A hydroxyl coating of the surface can suppress this effect.
A new surgical technique for deep brain stimulation (DBS) has been developed, allowing for more accurate placement of brain electrodes and reducing complications. The procedure is safer and faster than traditional DBS surgery, making it a promising treatment option for various medical conditions beyond Parkinson's disease.
A new study found that increased serum iron levels are associated with a 3% relative reduction in the risk of developing Parkinson's disease. The research used a Mendelian randomization approach to investigate the link between iron levels and Parkinson's disease risk.
The IUPUI research collaboration used advanced mathematical models and laboratory testing to examine the effects of simulated drug addiction on neural circuits. The study found that recurrent stimulant injections caused neurons to lose their ability to engage supervisory control over brain function and behavior.
A meta-analysis of over 100 studies found exposure to pesticides, weed killers, and solvents is associated with a higher risk of developing Parkinson's disease. The research suggests that the risk increases in a dose-response manner as length of exposure to these chemicals increases.
Scientists develop new animal model to study Parkinson's disease, tracing protein spreading in brain regions. The experiment reveals clues on mechanisms underlying pathological progression.
Defects in cellular trash removal processes lead to toxic protein build-up and neuronal damage in Gaucher disease, mirroring Parkinson's disease pathology. Researchers suggest targeting mitochondrial function to develop treatment strategies for both diseases.
Scientists have discovered a protein that binds to two 'orphan receptors' found in the brain, GPR37 and GPR37L1. This binding has been linked to neuroprotection and glioprotection, suggesting potential therapeutic applications for neurological diseases such as Parkinson's and stroke.
Researchers discover phosphatidylserine improves gene function in degenerative brain disorders, including Parkinson's disease and Familial Dysautonomia, slowing nerve cell death. The supplement is able to penetrate the blood-brain barrier, accumulating in sufficient amounts in the brain.
A clinical trial investigated the use of Exenatide, a diabetes drug, in patients with Parkinson's disease. The study found that patients receiving Exenatide showed significant improvements in motor skills and cognitive ability after one year of treatment.
McGill University researchers have discovered the three-dimensional structure of the Parkin protein, which protects neurons from cell death due to damaged mitochondria. The study's findings suggest that designing mutations in Parkin could provide better protection for nerve cells and potentially slow disease progression.
Research suggests that eating foods containing edible Solanaceae, such as peppers and tomatoes, may reduce risk of developing Parkinson's. The study found a strong association between increased consumption of these foods and decreased risk of Parkinson's, with peppers displaying the strongest association.
Researchers found that increasing parkin levels in fruit flies extended their life span by more than 25 percent, reducing damaged proteins and improving mitochondrial function. The study suggests that boosting cellular 'garbage disposal' could delay the onset of aging-related diseases like Parkinson's and Alzheimer's.
Scientists identify mitofusin 2 as key player linking mitochondrial quality control to Parkinson's disease and heart failure. The discovery may lead to new genetic forms of Parkinson's disease diagnosis and improved treatment options.
A new study reveals that Parkinson's disease protein alpha-synuclein can harm cells in the same way viruses do. It breaks out of lysosomes and releases enzymes toxic to the cell.
Researchers found that mannitol improved the movement of fruit flies with Parkinson's-like symptoms by reducing misfolded protein aggregation. Further studies are needed to confirm these results in humans, but the findings suggest a possible novel therapeutic direction.
Scientists have long debated the structure of alpha synuclein, a protein associated with Parkinson's. A new study models its structure, finding that it can rapidly switch between different conformations. The researchers suggest that stabilizing an ordered structure could prevent aggregation and offer a new drug-design strategy.
Researchers have discovered that Parkinson's disease protein, α-synuclein, forms insoluble aggregates that resist degradation in cells. The accumulation of these clumps impairs the macroautophagy system, a major garbage disposal system within the cell.
Laura Segatori, a Rice University engineer, has received a NSF CAREER Award to develop a toolkit for probing the workings of cellular processes that lead to diseases like Parkinson's. Her goal is to identify key proteins and learn how to regulate them using nanoparticles.
A Norwegian study found that patients with mild cognitive impairment (MCI) at Parkinson's disease diagnosis have a higher risk of developing early dementia. The study, which included 182 patients with PD, showed that more than 25% of those with MCI developed dementia within three years.
Researchers found that cognitively normal people with high amyloid levels are likelier to develop dementia. Mayo Clinic neurologists also developed a test to gauge concussion severity using autonomic reflex testing, and discovered heart attack victims who received therapeutic hypothermia are unlikely to suffer cognitive impairment.
Researchers at Columbia University Medical Center have made significant breakthroughs in treating rare genetic disorders. For one, they demonstrated the effectiveness of deoxypyrimidine monophosphates as a treatment for thymidine kinase 2 (TK2) deficiency, a condition causing devastating neuromuscular diseases. Additionally, studies on...
The Max Planck Florida Institute for Neuroscience received $1.257 million in grant funding to study Parkinson's and epilepsy. Researchers aim to develop new molecular tools to analyze the human brain, with potential breakthroughs in treatments and cures.
Researchers have identified promising treatments for three common challenges faced by people with Parkinson's disease: blood pressure problems, the wearing-off effect, and uncontrolled symptoms. The new drugs show promise in reducing dizziness, falls, and improving motor function, offering a brighter future for those affected.
A small study of 20 people with Parkinson's disease found virtual house calls provide clinical benefits comparable to in-person physician office visits, saving patients and caregivers time and travel. The study also found no difference in quality-of-life changes between the two groups.
Researchers have discovered a critical link between impaired protein digestion in neurons and familial Parkinson's disease. The study identifies LRRK2 mutations as a key contributor to alpha-synuclein accumulation, providing potential avenues for drug treatments or genetic therapies.
A new NIH-funded collaboration aims to accelerate the search for biomarkers in Parkinson's disease by improving collaboration among researchers and involving patients in clinical studies. The initiative, led by Dr. Clemens Scherzer at Brigham and Women's Hospital, seeks to develop biomarkers that can predict, diagnose, or monitor the d...
Scientists at UCSF have discovered a way to detect abnormal brain rhythms associated with Parkinson's disease by implanting electrodes within the brains of people with the disease. This finding may lead to developing next-generation brain stimulation devices to alleviate symptoms.
Researchers at Albert Einstein College of Medicine have discovered how the most common genetic mutations in familial Parkinson's disease damage brain cells. The study found that abnormal LRRK2 protein disrupts a 'garbage-disposal' process, leading to toxic levels of alpha-synuclein and neuronal death.
Researchers identified a novel signal transduction pathway that activates parkin and prevents stress-induced neuronal cell death in Parkinson's disease. The parkin gene plays a crucial role in maintaining mitochondrial integrity, which is essential for preventing cell death.
Miniature, ultra-flexible electrodes developed in Switzerland may improve Deep Brain Stimulation (DBS) treatment for Parkinson's disease and other conditions. These new electrodes allow for more precise directional stimulation, reducing side effects and enhancing therapeutic effectiveness.
Researchers at the University of York have established a link between Parkinson's and visual problems in an animal model. A study found that a common genetic mutation triggering Parkinson's affects eye nerve cell function, leading to gradual loss of vision.
Researchers identified a protein trafficking defect in brain cells that may underlie common non-familial forms of Parkinson's disease. The defect is related to genetic variants in two genes, LRRK2 and RAB7L1, which disrupt protein sorting and lead to the accumulation of protein aggregates.
A study published in JAMA Neurology found no evidence of human-to-human transmission of AD and PD protein in cadaver-derived hGH recipients, contradicting previous concerns. The research included 34 autopsy patients and a group of c-hGH recipients, yielding no cases of AD or PD.
The R1441G mutation, known as the Basque mutation, is a genetic variation that increases the risk of developing Parkinson's disease. A study published in Neurogenetics and Movement Disorders found that individuals carrying this mutation have an 83% chance of developing the disease by age 80.
Researchers have identified mitochondrial CYP2D6 as a potential target for mitigating Parkinson's disease. The study found that mitochondrial CYP2D6 can effectively metabolize MPTP, a compound causing brain cell damage in Parkinson's, and that inhibiting its activity reduces neuronal degeneration.
The NIH has launched a collaborative effort to find biomarkers for Parkinson's disease, which could help predict, diagnose, or monitor the condition. Researchers are exploring various approaches, including non-invasive imaging and protein analysis, to identify potential biomarkers that could improve treatment outcomes.
Research at Tel Aviv University finds that Parkinson's patients taking dopamine-enhancing medications are developing artistic talents, including painting, sculpting, and writing. The study suggests a link between dopamine levels and creativity, with some patients exhibiting increased impulsivity and lower inhibitions.
A new study published in Neurology shows that people with early Parkinson's disease often experience non-motor symptoms like anxiety, constipation, and drooling. These symptoms can significantly impact quality of life and are treatable if addressed.
Researchers found blocking JNK interaction with Sab can protect against neuronal damage, suggesting a potential new target for drug development. The study also showed that inhibiting JNK signaling leaves other cell signaling intact, which could mean fewer side effects in future therapies.
Researchers at Mayo Clinic have discovered that testing a portion of the saliva gland may diagnose Parkinson's disease more accurately. The study found abnormal proteins associated with the disease in nine out of 11 patients, offering hope for improved diagnosis and treatment.
Researchers have discovered a potential new method for diagnosing Parkinson's disease by testing the saliva gland. The study found that abnormal proteins associated with the disease were consistently present in the submandibular salivary glands of patients, suggesting this non-invasive test could be used to diagnose living individuals.
Researchers found no correlation between Parkinson's disease itself and impulse control symptoms, contradicting previous studies. The study suggests that dopamine-related medications may be the primary cause of these disorders.
Researchers found no link between untreated Parkinson's and impulse control disorders. However, studies suggest that exposure to dopamine-related drugs may increase impulsive behaviors in patients with the disease.
Researchers found that benomyl exposure can trigger a cascade of cellular events leading to Parkinson's disease, even in individuals without prior pesticide exposure. The study suggests developing new drugs to protect ALDH activity may slow disease progression.
A small stroke, known as a silent stroke, can cause Parkinson's disease by killing dopaminergic neurons in the substantia nigra. The study found inflammation and brain damage following the stroke, leading to neurodegeneration and potential onset of Parkinson's disease.